Myosin Therapeutics

About Myosin Therapeutics

The mission of Myosin Therapeutics, Inc. is to improve health outcomes through the development of novel pharmacotherapies targeting members of the myosin family of molecular motors. Myosin Therapeutics is positioned as the first nanomotor platform company focused on oncology, with a proprietary nMotor system for drug discovery. nMotor is a full screening platform from HTS to validation and target selectivity profiling, enabling Myosin to develop a robust pipeline of oncology therapeutics. Myosin has used nMotor to develop a unique therapeutic to improve outcomes in Glioblastoma (GBM), a critical unmet need with a conservative estimated serviceable market of at least 10,000 cases yearly in the US alone. Additionally, Myosin is developing a unique neurotherapeutic to prevent relapse in METH use disorder, another critical unmet need. METH use disorder is a chronic disorder for which there are currently no FDA-approved medications. More broadly, preclinical studies indicate that first-in-class pharmacotherapeutics targeting NMII have value in many applications, including other substance use disorders, cancer, neural regeneration and infectious diseases. Further, approval of a clinically safe NMII inhibitor will enable scientific advancements into the study of NMII’s contribution to human physiology, such as learning and memory.

View contact profiles from Myosin Therapeutics